Key result
Discharge statin therapy shows no association with lower mortality in Takotsubo syndrome.
Why the study?
Endothelial dysfunction plays a role in Takotsubo syndrome pathogenesis and statin therapy may improve endothelial function, but its impact on TTS outcomes is unclear.
Does statin therapy at discharge improve survival in patients with Takotsubo syndrome?
Cohort (n=2,429)
Yes
Does statin therapy at discharge improve survival in patients with Takotsubo syndrome?
Statin therapy at discharge in patients with Takotsubo syndrome is not associated with improved long-term survival.
Answers are grounded in this paper and cite their sources.
Statin discharge therapy should not yet alter management for survival in Takotsubo syndrome; leaves open whether RCTs would confirm this observational null finding.
BACKGROUND AND AIMS: Several studies have shown that endothelial dysfunction plays a role in the pathogenesis of Takotsubo syndrome (TTS). Given the potential benefit of statin therapy on endothelial dysfunction, we hypothesized that such treatment could improve outcome. Aim of our study was to evaluate clinical characteristics and outcome of TTS patients treated with statin therapy. METHODS: Patients were enrolled in the international multicenter GEIST (GErman Italian Spanish Takotsubo) registry. Demographic data, clinical features and drug therapy at discharge were recorded. Primary study outcome was the occurrence of all-cause death at follow-up. RESULTS: Study population included 2429 consecutive TTS patients: 1293 (53.2%) discharged on statin and 1136 (46.8%) without statin. Patients with statin were older (age 72 ± 11 vs 69 ± 13 years, p < 0.001), with higher prevalence of hypertension (74.3% vs 60.3%, p < 0.001), diabetes (21.1% vs 14.7%, p < 0.001), dyslipidemia (56.1% vs 23.3%, p < 0.001), history of coronary artery disease (13.3% vs 6.3%, p < 0.001) and lower rates of in-hospital complications (14.7% vs 19.3%, p = 0.003). Survival analysis showed similar mortality rates between groups (log rank p = 0.803). At univariable analysis, statin therapy at discharge was not associated with lower mortality (HR: 0.97, 95% CI 0.74-1.26, p = 0.803). At multivariable analysis age (HR: 1.06 95% CI 1.04-1.08, p < 0.001), male sex (HR: 1.83, 95% CI 1.20-2.80, p = 0.005), diabetes (HR: 2.55, 95% CI 1.83-3.54 p < 0.001), malignancies (HR: 2.41, 95% CI 1.68-3.44, p < 0.001) and physical trigger (HR: 2.24, 95% CI 1.62-3.10, p < 0.001) were associated with increased mortality. CONCLUSIONS: Statin therapy after a TTS event was not associated with better prognosis at follow-up.
No takes yet. Share an insight, caveat, or question.
Novo et al. (2023) conducted a cohort in Takotsubo syndrome (n=2,429). Statin therapy vs. No statin therapy was evaluated on All-cause death at follow-up (HR 0.97, 95% CI 0.74-1.26, p=0.803). Statin therapy at discharge in patients with Takotsubo syndrome was not associated with lower all-cause mortality at follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: